Urothelial Carcinoma
Advertisement
Results of the phase III BOND-003 trial show groundbreaking results of cretostimogene grenadenorepvec for NMIBC.
Treatment With Investigational TAR-200 Demonstrates Promising Results With BCG-Unresponsive HR NMIBC
TAR-200 monotherapy is well tolerated and shows promising efficacy in treating HR NMIBC, according to data from SunRISe-1. 
Durvalumab was granted FDA Priority Review for MIBC, after showing significant survival benefits in the NIAGARA trial.
TARA-002 shows promising efficacy, safety in the ADVANCED-2 trial for NMIBC, with high response rates across BCG exposures.
Robotic cystectomy after neoadjuvant immunotherapy shows higher severe complication rates than surgery alone.
In the final segment of the roundtable, the panel debates the real-world integration of new therapies into everyday practice.
In part five of this NMIBC roundtable, the panelists discuss integrating new therapies such as TAR-200 into clinical practice
Part four of this roundtable series examines the SunRISe-1 trial results for high-risk NMIBC.
The panelists discuss advancements in NMIBC treatment in part three of this roundtable, including pembrolizumab and TAR-200.
Part two of this roundtable explores intravesical and systemic therapies, and the importance of accurate risk stratification.
The first part of this roundtable focuses on recent trial data, the role of TUR quality, and precision medicine for NMIBC.
A recent study explored the impact of widely-used bladder cancer treatments on prevention, recurrence, and progression.
Ferring has advanced three clinical trials assessing nadofaragene as a monotherapy and combination therapy for NMIBC.
Dr. Li provides background and insights on the implications of his study on oncolytic immunotherapy with nivolumab for MIBC.
Locoregional recurrence can result in poor prognosis, and reported cases vary widely in medical literature.
IMvigor011 compared the efficacy of atezolizumab with placebo in patients with HR MIBC who remained ctDNA+ post-cystectomy.
Several posters and a late-breaking abstract will highlight data on cretostimogene grenadenorepvec for bladder cancer.
The study examined the prognostic value of ctDNA as a biomarker in patients with muscle-invasive bladder cancer.
The study explored how a micrometric substaging system for bladder cancer could improve the predictiveness of recurrence.
Dr. Brown shares highlights from the CME program at LUPGA 2024, including new trends in bladder, kidney, and prostate cancer.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.